393 related articles for article (PubMed ID: 33728437)
21. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
22. Comparing triage algorithms using HPV DNA genotyping, HPV E7 mRNA detection and cytology in high-risk HPV DNA-positive women.
Luttmer R; Berkhof J; Dijkstra MG; van Kemenade FJ; Snijders PJ; Heideman DA; Meijer CJ
J Clin Virol; 2015 Jun; 67():59-66. PubMed ID: 25959161
[TBL] [Abstract][Full Text] [Related]
23. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
[TBL] [Abstract][Full Text] [Related]
24. HPV testing in first-void urine provides sensitivity for CIN2+ detection comparable with a smear taken by a clinician or a brush-based self-sample: cross-sectional data from a triage population.
Leeman A; Del Pino M; Molijn A; Rodriguez A; Torné A; de Koning M; Ordi J; van Kemenade F; Jenkins D; Quint W
BJOG; 2017 Aug; 124(9):1356-1363. PubMed ID: 28391609
[TBL] [Abstract][Full Text] [Related]
25. [Performance of human papillomavirus typing test in cervical precancer lesions and cervical cancer screening].
Zhang SK; Luo XP; Li ZF; Su Z; Xia JC; Hu GY; Zhu YJ; Xie LX; Feng XX; Sun XB; Chen W; Qiao YL
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):252-256. PubMed ID: 32252206
[No Abstract] [Full Text] [Related]
26. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.
Manos MM; Kinney WK; Hurley LB; Sherman ME; Shieh-Ngai J; Kurman RJ; Ransley JE; Fetterman BJ; Hartinger JS; McIntosh KM; Pawlick GF; Hiatt RA
JAMA; 1999 May; 281(17):1605-10. PubMed ID: 10235153
[TBL] [Abstract][Full Text] [Related]
27. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of atypical glandular cells in Pap tests: An analysis of more than 3000 cases at a large academic women's center.
Pradhan D; Li Z; Ocque R; Patadji S; Zhao C
Cancer Cytopathol; 2016 Aug; 124(8):589-95. PubMed ID: 27115423
[TBL] [Abstract][Full Text] [Related]
29. Significance of high-risk HPV detection in women with atypical glandular cells on Pap testing: Analysis of 1857 cases from an academic institution.
Patadji S; Li Z; Pradhan D; Zhao C
Cancer Cytopathol; 2017 Mar; 125(3):205-211. PubMed ID: 28060456
[TBL] [Abstract][Full Text] [Related]
30. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
[TBL] [Abstract][Full Text] [Related]
31. Linear array genotyping and hybrid capture II assay in detecting human papillomavirus genotypes in women referred for colposcopy due to abnormal Papanicolaou smear.
Monsonego J; Pollini G; Evrard MJ; Sednaoui P; Monfort L; Quinzat D; Dachez R; Syrjänen K
Int J STD AIDS; 2008 Jun; 19(6):385-92. PubMed ID: 18595876
[TBL] [Abstract][Full Text] [Related]
32. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico.
Salmerón J; Lazcano-Ponce E; Lorincz A; Hernández M; Hernández P; Leyva A; Uribe M; Manzanares H; Antunez A; Carmona E; Ronnett BM; Sherman ME; Bishai D; Ferris D; Flores Y; Yunes E; Shah KV
Cancer Causes Control; 2003 Aug; 14(6):505-12. PubMed ID: 12948281
[TBL] [Abstract][Full Text] [Related]
33. Aptima HPV messenger RNA testing and histopathologic follow-up in women with HSIL cytology: A study emphasizing additional review of HPV-negative cases.
Li A; Li J; Austin RM; Wang T; Ashman D; Zhang H; Matsko J; Zhao C
Cancer Cytopathol; 2021 Aug; 129(8):622-631. PubMed ID: 33764649
[TBL] [Abstract][Full Text] [Related]
34. Safety of screening with Human papillomavirus testing for cervical cancer at three-year intervals in a high-risk population: experience from the LAMS study.
Derchain SF; Sarian LO; Naud P; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Serpa-Hammes L; Matos J; Gontijo RC; Bragança JF; Lima TP; Maeda MY; Lörincz A; Dores GB; Costa S; Syrjänen S; Syrjänen K
J Med Screen; 2008; 15(2):97-104. PubMed ID: 18573778
[TBL] [Abstract][Full Text] [Related]
35. Assessment of reflex human papillomavirus DNA testing in patients with atypical endocervical cells on cervical cytology.
Chen L; Yang B
Cancer; 2008 Aug; 114(4):236-41. PubMed ID: 18548530
[TBL] [Abstract][Full Text] [Related]
36. Atypical squamous cells of undetermined significance in liquid-based cytologic specimens: results of reflex human papillomavirus testing and histologic follow-up in routine practice with comparison of interpretive and probabilistic reporting methods.
Levi AW; Kelly DP; Rosenthal DL; Ronnett BM
Cancer; 2003 Aug; 99(4):191-7. PubMed ID: 12925979
[TBL] [Abstract][Full Text] [Related]
37. Human papillomavirus testing versus cytology in primary cervical cancer screening: End-of-study and extended follow-up results from the Canadian cervical cancer screening trial.
Isidean SD; Mayrand MH; Ramanakumar AV; Gilbert L; Reid SL; Rodrigues I; Ferenczy A; Ratnam S; Coutlée F; Franco EL;
Int J Cancer; 2016 Dec; 139(11):2456-66. PubMed ID: 27538188
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of HPV-16/18 genotypes and immediate histopathologic correlation results in a Chinese population with negative cytology and positive high-risk HPV testing.
Tao X; Zhang H; Li J; Zhang H; Xiao J; Zhang L; Zhou X; Sui L; Wang L; Zhao C
Cancer Cytopathol; 2019 Oct; 127(10):650-657. PubMed ID: 31532582
[TBL] [Abstract][Full Text] [Related]
39. Sensitivity of high-risk HPV Hybrid Capture II (hrHPV HC2) test using SurePath(TM) specimens in the prediction of cervical high-grade squamous lesions.
Zhou F; Pulinthanathu R; Elgert P; Cangiarella J; Simsir A
Diagn Cytopathol; 2015 May; 43(5):381-7. PubMed ID: 25546355
[TBL] [Abstract][Full Text] [Related]
40. Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women.
Jiang MY; Wu Z; Li T; Yu L; Zhang SK; Zhang X; Qu P; Sun P; Xi MR; Liu X; Liao G; Sun L; Zhang Y; Chen W; Qiao YL
Cancer Prev Res (Phila); 2020 Feb; 13(2):163-172. PubMed ID: 31871224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]